Neuendorfstrasse 15a
Hennigsdorf 16761
Germany
49 3302 20 77 824
https://www.dbi-ag.de
Sektor(en):
Branche:
Vollzeitmitarbeiter:
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Dr. Bernd Wegener FRICS | Chairman of Management Board & Chief Executive Officer | N/A | N/A | 1947 |
Dr. Metod Miklus | COO & Member of Management Board | N/A | N/A | 1959 |
Dr. Frauke Hein Ph.D. | Chief Business Officer & Head of Business Development | N/A | N/A | N/A |
Dr. Joachim Struck | Head of Research & Development | N/A | N/A | N/A |
Dr. Jens Zimmermann | Chief Medical Officer | N/A | N/A | N/A |
Deutsche Biotech Innovativ AG operates as a biotechnology company in Germany. The company develops Adrecizumab, an antibody-based therapy that has completed the Phase I/II clinical trial for the treatment of septic shock. It also focuses on the development of various drugs for the treatment of solid tumor, organ failure, rosacea, neurodermatitis, pharyngitis, and Alzheimer's diseases. The company was formerly known as Venetus Beteiligungen AG and changed its name to Deutsche Biotech Innovativ AG in August 2014. Deutsche Biotech Innovativ AG was founded in 2009 and is based in Hennigsdorf, Germany.
Deutsche Biotech Innovativ AGs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.